Cambridge, MA, United States of America

Jonathan C Man



Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 14(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Pulmonary Delivery: The Contributions of Jonathan C. Man

Introduction

Jonathan C. Man, esteemed inventor based in Cambridge, MA, holds a significant patent that has implications for pulmonary treatments against infectious diseases. His innovative work aims to enhance the administration of medications through formulations designed to reduce particle exhalation.

Latest Patents

Jonathan C. Man's patent focuses on "Formulations Decreasing Particle Exhalation". This groundbreaking formulation has been developed for pulmonary delivery to effectively treat or diminish the infectivity of various diseases like viral infections, including tuberculosis, SARS, and influenza, as well as respiratory syncytial virus in humans. The formulation is also aimed at addressing hoof and mouth disease in animals, allergies, and other pulmonary conditions. By altering the physical properties of lung mucus lining fluid, this formulation may include isotonic saline and a suitable carrier. It is versatile, allowing administration as a liquid solution, suspension, aerosol, or powder, with the potential inclusion of antivirals or antibiotics.

Career Highlights

Jonathan C. Man works at Pulmatrix, Inc., a company renowned for its focus on developing inhalation therapies. His research and development efforts contribute to the advancement of delivery methods for critical medications, thereby improving health outcomes for patients with infectious diseases.

Collaborations

In his professional journey, Jonathan collaborates closely with notable peers such as David A. Edwards and Jeffrey P. Katstra. These collaborations underscore the importance of teamwork in generating innovative solutions in the field of healthcare.

Conclusion

Jonathan C. Man's contributions to the field of pulmonary delivery signify a notable advancement in medical science. His patent for formulations that decrease particle exhalation represents a significant step toward more effective treatment options for both humans and animals, potentially transforming the landscape of respiratory disease management.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…